The Federal Reserve held rates in July by a 9-3 vote, and all three dissenters wanted them higher. That detail was absent from the July statement and surfaced only when the minutes landed on Wednesday afternoon in Washington. Beth Hammack, Neel Kashkari and Lorie Logan each preferred a quarter-point increase to the 3.50%-3.75% target range. Equities closed higher regardless: the S&P 500 added 0.21% to 7,707.98, the Nasdaq Composite 0.16% to 26,331.09 and the Dow 0.22% to 53,463.05, snapping a three-day slide.

Three passages deserved more attention than the tape gave them.

1. The tightening camp is larger than the vote count. Beyond the three dissents, “several participants favored an increase of 25 basis points in the target range at this meeting,” and “many participants assessed that policy tightening would likely be necessary if inflation did not decline.” Some questioned whether financial conditions were restrictive enough to return inflation to 2%. Nowhere in the document does a participant argue for a cut.

2. Tariffs have stopped being the alibi. Total PCE inflation ran at 4.1% in May with core at 3.4%, and staff estimated June at 3.7% and 3.3%. Several participants judged the pass-through of past tariff increases into prices “largely complete,” which reframes what remains as underlying inflation rather than a one-time level shift. Participants judged inflation risks skewed to the upside.

3. The labour market offers no cover. Unemployment sat at 4.2%, labour demand and supply were described as in balance, and several participants noted that AI-related uncertainty was keeping both hiring and firing low. A committee worried about prices and untroubled by employment has little reason to wait.

The mechanism runs through the discount rate. A path that turns toward tightening rather than easing lifts the rate applied to future earnings and compresses multiples, long-duration growth names most acutely. Wednesday’s tape ignored it. Long-end pressure eased and stock-specific news dominated, with Moderna more than doubling on Phase 3 melanoma data, Merck up 12.6% alongside it, and Target gaining 4.3% on a 5.3% sales increase. Attribution to the minutes at index level is weak, and pretending otherwise would overstate the case. Markets had gone into the July meeting pricing roughly a one-in-three chance of an increase, so the direction of the debate was not entirely a surprise; the size of the hawkish bloc was. With the 10-year sitting near 4.71%, the bond market was already carrying a good deal of that hawkishness before the minutes confirmed it.

One number is worth holding onto. The same minutes recorded equity valuations at a level that “has only been lower in recent history during the dot-com bubble.”

For more, browse our full equity research reports, check the earnings calendar for what's coming up, or head back to the blog for the latest updates.